Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)

被引：0

作者：

Velez, L. ^{[1
,2
]}

Trevino, T. ^{[4
]}

Kopetz, S. ^{[3
]}

Grothey, A. ^{[4
]}

Yaeger, R. ^{[5
]}

Gollerkeri, A. ^{[6
]}

Maharry, K. ^{[6
]}

Tabernero, J. ^{[1
,2
]}

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Vall dHebron Inst Oncol, Barcelona, Spain

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Univ Tennessee, West Canc Ctr, Germantown, TN USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Pfizer Inc, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.04.036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SO-21

引用

页码：S224 / S225

页数：2

共 50 条

[21] Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
Trouiller, Jean-Baptiste
Macabeo, Berengere
Poll, Andrew
Howard, Dan
Buckland, Andy
Sivignon, Marine
Clay, Emilie
Malka, David
Samalin, Emmanuelle
Toumi, Mondher
Laramee, Philippe
[J]. BMJ OPEN, 2022, 12 (11):
[22] BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer
Desai, Jayesh
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia Alfonso, Pilar
Price, Timothy
Strickland, Andrew
Tebbutt, Niall
Karapetis, Christos
Chantrill, Lorraine
Murphy, Felicity
Sandor, Victor
Christy-Bittel, Janna
Anderson, Lisa
Tabernero, Josep
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 99 - 99
[23] A Phase Ib/II Study of WNT974+Encorafenib plus Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
Tabernero, Josep
Van Cutsem, Eric
Garralda, Elena
Tai, David
De Braud, Filippo
Geva, Ravit
van Bussel, Mark T. J.
Fiorella Dotti, Katia
Elez, Elena
de Miguel, Maria J.
Litwiler, Kevin
Murphy, Danielle
Edwards, Michelle
Morris, Van Karlyle
[J]. ONCOLOGIST, 2023, : 230 - 238
[24] Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
Ros, Javierd
Saoudi, Nadia
Baraibar, Iosune
Salva, Francesc
Tabernero, Josep
Elez, Elena
[J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
[25] Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer
Yamaguchi, Toshifumi
Daisuke, Kotani
Atsuo, Takashima
Takeshi, Kato
Toshiki, Masuishi
Yoshito, Komatsu
Manabu, Shiozawa
Taito, Esaki
Naoki, Izawa
Shinji, Takeuchi
Hideaki, Bando
Satoru, Iwasa
Hiroko, Hasegawa
Taroh, Satoh
Hiroya, Taniguchi
Takayuki, Yoshino
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S479 - S479
[26] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Keir, Christopher Hunt
Pickard, Michael D.
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[27] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Kyrre Guren, Tormod
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Hunt Keir, Christopher
Pickard, Michael D.
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[28] Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)
Vogel, Arndt
Hegewisch-Becker, Susanna
Prager, Gerald
Folprecht, Gunnar
Stahl, Michael
Kopetz, Scott
Grothey, Axel
van Cutsetn, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Desai, Jayesh
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Loupakis, Fotios
Hong, Y.
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfons, Pilar
Sandor, Victor
Christy-Bittel, Farina
Anderson, Lisa
Tabernero, Josep
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 55 - 55
[29] Encorafenib, binimetinib, and cetuximab combination therapy for patients with BRAF V600E mutant colorectal cancer
Moro, Kazuki
Saiki, Takuro
Sasaki, Kenta
Matsumoto, Akio
Zhou, Qiliang
Nakano, Mae
Nakano, Masato
Matsumoto, Yoshifumi
Shimada, Yoshifumi
Moriyama, Masato
Wakai, Toshifumi
Saijo, Yasuo
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S541 - S541
[30] TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E-mutant metastatic colorectal cancer.
Kotani, Daisuke
Kagawa, Yoshinori
Matsubara, Yuki
Bando, Hideaki
Harada, Kazuaki
Takahashi, Naoki
Mihara, Yoshiaki
Nakayama, Izuma
Izawa, Naoki
Kawakami, Takeshi
Masuishi, Toshiki
Hasegawa, Hiroko
Ohta, Takashi
Wakabayashi, Masashi
Yoshino, Takayuki
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS264 - TPS264

← 1 2 3 4 5 →